Substrate reduction augments the efficacy of enzyme therapy in a mouse model of fabry disease

PLoS ONE

Volumn 5, Issue 11, 2010, Pages

  Marshall, John ^a   Ashe, Karen M ^a   Bangari, Dinesh ^a   McEachern, KerryAnne ^a   Chuang, Wei Lien ^a   Pacheco, Joshua ^a   Copeland, Diane P ^a   Desnick, Robert J ^b   Shayman, James A ^c   Scheule, Ronald K ^a   Cheng, Seng H ^a  

^a GENZYME CORPORATION   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE; CERAMIDE GLUCOSYLTRANSFERASE INHIBITOR; ELIGLUSTAT TARTRATE; GENZ 112638; GLOBOTRIAOSYLCERAMIDE; TAMM HORSFALL GLYCOPROTEIN; UNCLASSIFIED DRUG; CERAMIDE GLUCOSYLTRANSFERASE; CERAMIDE TRIHEXOSIDE; GENZ-112638; GLUCOSYLTRANSFERASE; PYRROLIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME REPLACEMENT; FABRY DISEASE; HEART; KIDNEY; LIVER; MOUSE; NOCICEPTION; NONHUMAN; SUBSTRATE REDUCTION THERAPY; THERAPY; URINE VOLUME; 129 MOUSE; ANIMAL; DISEASE MODEL; DRUG ANTAGONISM; DRUG COMBINATION; DRUG POTENTIATION; FEMALE; GENETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; MOUSE MUTANT; TREATMENT OUTCOME; URINE;

ALPHA-GALACTOSIDASE; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; FEMALE; GLUCOSYLTRANSFERASES; HUMANS; MALE; MASS SPECTROMETRY; MICE; MICE, 129 STRAIN; MICE, KNOCKOUT; PYRROLIDINES; TREATMENT OUTCOME; TRIHEXOSYLCERAMIDES; UROMODULIN;

EID: 78649677073     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015033     Document Type: Article

References (40)

1. Desnick R, Ioannou Y, Eng C (2001) α-Galactosidase A deficiency: Fabry disease. In Scriver C, Beaudet A, Sly W, Valle D, eds. The Metabolic and Molecular Basis of Inherited Disease (8th ed.), McGraw-Hill, New York. pp 3733-3774.
2. Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P (2009) Life expectancy and cause of death in males and females with Fabry disease: Findings from the Fabry Registry. Genet Med 11: 790-796.
3. Schiffman R, Ries M, Timmons M, Flaherty JT, Brady RO (2006) Long-term therapy with agalsidase alfa for Fabry disease: safety effects on renal function in a home infusion setting. Nephrol Dial Transplant 21: 345-354.
4. Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, et al. (2007) Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 18: 1547-1557.
5. Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, et al. (2007) Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146: 77-86.
6. Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, et al. (2004) Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 75: 65-74.
7. Vedder AC, Linthorst GE, Houge G, Groener JE, Ormel EE, et al. (2007) Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2mg/kg. PLoS ONE 2: e598.
8. Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, et al. (2002) Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 62: 1933-1946.
9. Platt FM, Lachmann RH (2009) Treating lysosomal storage disorders: Current practice and future prospects. Biochim Biophys Acta 1793: 737-745.
10. Cox TM, Aerts JM, Andria G, Beck M, Belmatoug N, et al. (2003) The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type 1 (non-neuropathic) Gaucher disease: a position statement. J Inherit Metab Dis 26: 513-526.
11. Lukina E, Watman N, Arreguin EA, Banikazemi M, Dragosky M, et al. (2010) A Phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood 116: 893-899.
12. Abe A, Gregory S, Lee L, Killem PD, Brady RO, et al. (2000) Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation. J Clin Invest 105: 1563-1571.
13. Shu L, Murphy HS, Cooling L, Shayman JA (2005) An in Vitro Model of Fabry Disease. J Am Soc Nephrol 16: 2636-2645.
14. Heare T, Alp NJ, Priestman DA, Kulkarni AB, Qasba P, et al. (2007) Severe endothelial dysfunction in the aorta of a mouse model of Fabry disease; partial prevention by N-butyldeoxynojirimycin treatment. J Inherit Metab Dis 30: 79-87.
15. Pastores GM, Barnett NL, Kolodny EH (2005) An open-label, noncomparative study of miglustat in type 1 Gaucher disease: efficacy and tolerability over 24 months of treatment. Clin Ther 27: 1215-1227.
16. Hollak CE, Hughes D, van Schaik IN, Schwierin N, Bembi B (2009) Miglustat (ZavescaH) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme. Pharmacoepidemiol Drug Saf 18: 770-777.
17. Hoffman B, Schwarz M, Mehta A, Keshav S (2007) Gastrointestinal symptoms in 342 Patients with Fabry Disease: Prevalence and response to enzyme replacement therapy. Clin Gastroent Hepat 12(5): 1447-1453.
18. McEachern K, Fung J, Komarnitsky S, Siegel CS, Chuang W-L, et al. (2007) A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Molec Genet Metab 91: 259-267.
19. Marshall J, McEachern KA, Chuang W-L, Hutto E, Siegel CS, et al. (2010) Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy. J Inherit Metab Dis 33: 281-289.
20. Wang AM, Ioannou YA, Zeidner KM, Gotleb RW, Dikman S, et al. (1996) Generation of a mouse model with α-galactosidase A deficiency. Am J Hum Genet 59: A208.
21. Ohshima T, Murray GJ, Swaim WD, Longenecker G, Quirk JM, et al. (1997) Alpha-galactosidase A deficient mice: a model of Fabry disease. Proc Natl Acad Sci USA 94: 2540-2544.
22. Moore DF, Gelderman MP, Fuhrmann SR, Schiffmann R, Brady RO, et al. (2006) Fabry disease and vascular risk factors: future strategies for patient-based studies and the knockout murine model. Acta Paediatrica S451: 69-71.
23. Ziegler RJ, Cherry M, Barbon CM, Li C, Bercury SD, et al. (2007) Correction of the biochemical and functional deficits in Fabry mice following AAV8-mediated hepatic expression of α-galactosidase A. Molec Ther 15: 492-500.
24. Rodrigues LG, Ferraz MJ, Rodrigues D, Pais-Vieira M, Lima D, et al. (2009) Neurophysiological, behavioral and morphological abnormalities in the Fabry knockout mice. Neurobiol Dis 33: 48-56.
25. Sessa A, Meroni M, Battini G, Righetti A, Maglio A, et al. (2003) Renal involvement in Anderson-Fabry disease. J Nephrol 16: 310-313.
26. Schiffmann R, Askari H, Timmons M, Robinson C, Benko W, et al. (2007) Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing. J Am Soc Nephrol 18: 1576-1583.
27. Ohshima T, Schiffmann R, Murray GJ, Kopp J, Quirk JM, et al. (1999) Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice. Proc Natl Acad Sci USA 96: 6423-6427.
28. Dutsch M, Marthol H, Stemper B, Brys M, Haendl T, et al. (2002) Small fiber dysfunction predominates in Fabry neuropathy. J Clin Neurophys 19: 575-586.
29. Torvin Moller A, Winther Bach F, Feldt-Rasmusen U, Rasmussen A, Hasholt L, et al. (2009) Functional and structural nerve fiber findings in heterozygote patients with Fabry disease. Pain 145: 237-245.
30. Luciano CA, Russell JW, Banerjee TK, Quirk JM, Scott LJC, et al. (2002) Physiological characterization of neuropathy in Fabry's disease. Muscle & Nerve 26: 622-629.
31. Schiffmann R, Scott LJC (2002) Pathophysiology and assessment of neuropathic pain in Fabry disease, Acta Paediatrica. International Journal of Paediatrics Supplement 91(439): 48-52.
32. Vylet'al P, Hulkova H, Zivna M, Berna L, Novak P, et al. (2008) Abnormal expression and processing of uromodulin in Fabry disease reflects tubular cell storage alteration and is reversible by enzyme replacement therapy. J Inherit Metab Dis 31: 508-517.
33. Gadoth N, Sandbank U (1983) Involvement of dorsal root ganglia in Fabry's disease. J Mol Genet 20: 309-313.
34. Lidove O, Joly D, Barbey F, Bekri S, Alexandra J-F, et al. (2007) Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature. Int J Clin Pract 61: 293-302.
35. Thurberg BL, Fallon JT, Mitchell R, Aretz T, Gordon RE, et al. (2009) Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy. Circulation 119: 2561-2567.
36. Shu L, Shayman JA (2007) Caveolin-associated accumulation of globotriaosylceramide in the vascular endothelium of α-galactosidase A null mice. J Biol Chem 282: 20960-20967.
37. Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, et al. (2008) Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry. Molec Genet Metab 93: 112-128.
38. Kobayashi M, Ohashi T, Sakuma M, Ida H, Eto Y (2008) Clinical manifestations and natural history of Japanese heterozygous females with Fabry disease. J Inherit Metab Dis Online Report #003 DOI 10.1007/s10545-007- 0740-6.
39. Wilson Crosbie T, Packman W, Packman S (2009) Psychological aspects of patients with Fabry disease. J Inherit Metab Dis 32: 745-753.
40. Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, et al. (1992) RAG-1-Deficient mice have no mature B and T lymphocytes. Cell 68: 869-877.